Durham R A, Johnson J D, Eaton M J, Moore K E, Lookingland K J
Department of Pharmacology and Toxicology, Michigan State University, East Lansing 48824, USA.
Eur J Pharmacol. 1998 Aug 21;355(2-3):141-7. doi: 10.1016/s0014-2999(98)00498-1.
The purpose of the present study was to characterize pharmacologically dopamine D1 receptor-mediated inhibition of tuberoinfundibular dopamine neurons in males rats, and to determine if inhibitory dopamine D1 receptors oppose stimulatory dopamine D2 receptors and account for the inability of mixed dopamine receptor agonists to alter the activity of these neurons. Tuberoinfundibular dopamine neuronal activity was estimated by measuring the concentrations of the dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC) in the median eminence, the region of the hypothalamus containing terminals of these neurons. Administration of the dopamine D1 receptor agonist (+/-)-1 phenyl-2,3,4,5-tetrahydro-(1 H)-3-benzazepine-7,8-diol (SKF38393) decreased median eminence DOPAC and increased plasma prolactin concentrations, whereas administration of the dopamine D1 receptor antagonist ((-)-trans,6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H -benzo[d]naphtho-[2,1 b]azepine (SCH39166) increased median eminence DOPAC concentrations but had not effect on plasma prolactin. The inhibitory effect of SKF38393 on median eminence DOPAC concentrations was blocked by SCH39166. These results demonstrate that acute activation of dopamine D1 receptors inhibits the activity of tuberoinfundibular dopamine neurons and thereby increases prolactin secretion, and that under basal conditions dopamine D1 receptor-mediated inhibition of tuberoinfundibular dopamine neurons is tonically active. Administration of the dopamine D2 receptor agonist (5aR-trans)-5,5a,6,7,8,9,9a,10-octahydro-6-propyl-pyridol[2, 3-g]quinazolin-2-amine (quinelorane) increased median eminence DOPAC concentrations, and SKF38393 caused a dose-dependent reversal of this effect. Administration of the mixed dopamine D1/D2 receptor agonist R(-)-10,11-dihydroxy-apomorphine (apomorphine) had no effect per se, but blocked quinelorane-induced increases in DOPAC concentrations in the median eminence. These results reveal that concurrent activation of dopamine D1 and D2 receptors nullifies the actions of each of these receptors on tuberoinfundibular dopamine neurons, which likely accounts for the lack of an acute effect of mixed dopamine D1/D2 receptor agonists on these hypothalamic dopamine neurons.
本研究的目的是从药理学角度描述多巴胺D1受体介导的对雄性大鼠结节漏斗部多巴胺能神经元的抑制作用,并确定抑制性多巴胺D1受体是否与刺激性多巴胺D2受体相互拮抗,以及是否解释了混合多巴胺受体激动剂无法改变这些神经元活性的原因。通过测量正中隆起(下丘脑的一个区域,包含这些神经元的终末)中多巴胺代谢产物3,4-二羟基苯乙酸(DOPAC)的浓度来估计结节漏斗部多巴胺能神经元的活性。给予多巴胺D1受体激动剂(±)-1-苯基-2,3,4,5-四氢-(1H)-3-苯并氮杂卓-7,8-二醇(SKF38393)可降低正中隆起DOPAC浓度并升高血浆催乳素浓度,而给予多巴胺D1受体拮抗剂(-)-反式,6,7,7a,8,9,13b-六氢-3-氯-2-羟基-N-甲基-5H-苯并[d]萘并[2,1b]氮杂卓(SCH39166)可升高正中隆起DOPAC浓度,但对血浆催乳素无影响。SKF38393对正中隆起DOPAC浓度的抑制作用被SCH39166阻断。这些结果表明,多巴胺D1受体的急性激活抑制了结节漏斗部多巴胺能神经元的活性,从而增加了催乳素的分泌,并且在基础条件下,多巴胺D1受体介导的对结节漏斗部多巴胺能神经元的抑制作用具有紧张性活性。给予多巴胺D2受体激动剂(5aR-反式)-5,5a,6,7,8,9,9a,10-八氢-6-丙基-吡啶并[2,3-g]喹唑啉-2-胺(喹洛雷)可升高正中隆起DOPAC浓度,而SKF38393可导致这种作用的剂量依赖性逆转。给予混合多巴胺D1/D2受体激动剂R(-)-10,11-二羟基阿扑吗啡(阿扑吗啡)本身无作用,但可阻断喹洛雷诱导的正中隆起DOPAC浓度升高。这些结果表明,多巴胺D1和D2受体的同时激活使这些受体对结节漏斗部多巴胺能神经元的各自作用失效,这可能解释了混合多巴胺D1/D2受体激动剂对这些下丘脑多巴胺能神经元缺乏急性作用的原因。